<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826965</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00105056</org_study_id>
    <nct_id>NCT04826965</nct_id>
  </id_info>
  <brief_title>VAC Bioburden Wound Care Assessment</brief_title>
  <official_title>Does Negative Pressure Wound Therapy With Instillation Reduce the Bioburden of Infections of the Upper and Lower Extremity?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the microbiologic burden and need for further&#xD;
      operative debridement of patients undergoing primary surgical debridement of infected tissue,&#xD;
      soft tissue abscesses, or traumatic wounds of the upper and lower extremity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial bio-burden as measured by quantitative microbial PCR prior to debridement,&#xD;
      immediately following initial debridement, after 2 days of VAC veraflo (or conventional VAC)&#xD;
      therapy, and at the time of repeat operative debridements, if needed. We will use the&#xD;
      MicroGen PCR platform (DBA Microgen Diagnostics, LLC, Lubbock, TX.) to report on the&#xD;
      bacterial burden (reported on a log scale of bacteria per gram) present at the time of&#xD;
      debridement. Our goal is to be able to assess the bioburden quantitatively at each time point&#xD;
      to discern a change.&#xD;
&#xD;
      Exploratory outcomes to be measured: number of operative debridements required prior to&#xD;
      reconstruction, number of days until final reconstruction, number of days until decision is&#xD;
      made by surgeon that further debridements are no longer necessary, length of hospital stay,&#xD;
      wound surface area will be monitored from enrollment through when the veraflo is removed.&#xD;
      This is likely a 3-month interval.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Screen 60 subjects in hopes to enroll 40. There will be 20 subjects per arm. All subjects will have a wound vac applied. The randomization will be whether or not irrigation is included.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bio-burden as measured by quantitative microbial PCR</measure>
    <time_frame>Enrollment - 3 months post-surgery</time_frame>
    <description>Bacterial bio-burden as measured by quantitative microbial PCR prior to debridement, immediately following initial debridement, after 2 days of VAC veraflo (or conventional VAC) therapy, and at the time of repeat operative debridements, if needed. We will use the MicroGen PCR platform (DBA Microgen Diagnostics, LLC, Lubbock, TX.) to report on the bacterial burden (reported on a log scale of bacteria per gram) present at the time of debridement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Upper Extremity Wound</condition>
  <condition>Lower Extremity Wound</condition>
  <condition>Soft Tissue Abscesses</condition>
  <condition>Traumatic Wounds</condition>
  <arm_group>
    <arm_group_label>Wound vac application</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wound vac application for open upper/lower extremity open wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wound vac application including irrigation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wound vac application WITH irrigation for upper/lower extremity open wound</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wound Vac is applied</intervention_name>
    <description>A wound vac or wound vac with cleanse choice dressing, track pad duo, and saline irrigation is applied.</description>
    <arm_group_label>Wound vac application</arm_group_label>
    <arm_group_label>Wound vac application including irrigation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18+yo with an injury or infection of the upper or lower extremity for which surgical&#xD;
             debridement (in the operating room) followed by VAC application is planned.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patient with wounds distal to the ankle.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suhail Mithani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suhail Mithani</last_name>
    <phone>919-684-8111</phone>
    <email>suhail.mithani@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gallagher, BA</last_name>
      <phone>919-970-1551</phone>
      <email>jennifer.gallagher@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Suhail Mithani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

